ViroPharma has initiated a Phase II dose-ranging clinical study in North America of VP 20621, its drug to prevent recurrences of Clostridium difficile infection in adults previously treated with antibiotics.
ViroPharma has initiated a Phase II dose-ranging clinical study in North America of VP 20621, its drug to prevent recurrences of Clostridium difficile infection in adults previously treated with antibiotics.
VP 20621 is a non-toxin producing C difficile spore preparation, which acts as a probiotic. The aim is to colonise...
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
The Austrian firm is delisting from the NASDAQ and closing down.
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.
